Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

LignaMed LLC
Profile last edited on: 9/26/22      CAGE: 6WNG9      UEI: C8L8WEU3TE85

Business Identifier: Oral treatment for pulmonary fibrosis
Year Founded
2013
First Award
2017
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

3711 Market Street
Philadelphia, PA 19104
   (215) 206-2754
   N/A
   lignamed.com
Location: Single
Congr. District: 03
County: Philadelphia

Public Profile

LignaMed LLC is a biopharmaceutical company that has discovered a treatment for pulmonary fibrosis and other lung diseases. The solution is LGM 2605, this oral treatment is reversing the disease and improving patient's lives.

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
3
Conversion Rate
75.00%
Phase I Dollars
$1,002,078
Phase II Dollars
$6,075,253
Total Awarded
$7,077,331

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 2 NIH $2,655,879
Project Title: Optimization of LGM2605 for Use as a Device in Lung Transplant
2021 2 NIH $3,242,087
Project Title: Effects of LGM2605 on a Primate Model of Asthma
2018 2 NASA $879,766
Project Title: LGM2605 as a Mitigator of Space Radiation-Induced Vascular Damage
2018 1 NIH $299,599
Project Title: Graft-Protective Properties of LGM2605 in Lung Transplantation

Key People / Management

  Jim Harris -- CEO

  Melpo Christofidou-Solomidou

  Thais M Sielecki -- CSO

Company News

There are no news available.